(Q46254758)

20 December 2017

title

Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection (English)

1 reference

20 December 2017

author name string

Dosanjh A

series ordinal

1

1 reference

20 December 2017

language of work or name

English

0 references

publication date

1 September 2007

1 reference

20 December 2017

Transplantation Proceedings

published in

1 reference

20 December 2017

volume

39

1 reference

20 December 2017

issue

7

1 reference

20 December 2017

page(s)

2153-2156

1 reference

20 December 2017

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

TIA-1 is a translational silencer that selectively regulates the expression of TNF-alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Effect of pirfenidone on induction of chemokines in rat hepatocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a three-dose bleomycin-hamster model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

A prominent role for Sp1 during lipopolysaccharide-mediated induction of the IL-10 promoter in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone effectively reverses experimental liver fibrosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Phase II trial of pirfenidone in adults with neurofibromatosis type 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2007.07.078

10.1016/J.TRANSPROCEED.2007.07.078

7 January 2021

Identifiers

DOI

1 reference

20 December 2017

1 reference

20 December 2017